Overview

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

Status:
Not yet recruiting

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

To search for a Maximum Tolerated Dose (MTD) for the combination of daratumumab and induction chemotherapy with Idarubicin and cytarabine in patients with Acute Myeloblastic Leukemia (AML) of poor prognosis

Phase:

Phase 1

Details

Lead Sponsor:

Nantes University Hospital

Treatments:

Daratumumab